The CanStem111P study (ClinicalTrials.gov Identifier: NCT02993731) included 1134 adults with treatment-naive, metastatic pancreatic adenocarcinoma who were randomly assigned to receive nab-paclitaxel and gemcitabine (569 patients) or napabucasin plus nab-paclitaxel and gemcitabine (565 patients). Read more . . .
Adding napabucasin to frontline treatment with nab-paclitaxel and gemcitabine does not improve response or survival outcomes in patients with metastatic pancreatic adenocarcinoma, according to results of a phase 3 trial presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2021.